AN2 Therapeutics, Inc. (ANTX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -38.81M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 26.64M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-38.81M | (m) | (m) | $26.64M | (m) | (m) |
| 2026-03-31 | $-37.12M | (m) | (m) | $23.82M | (m) | (m) |
| 2025-12-31 | $-38.11M | (m) | (m) | $24.77M | (m) | (m) |
| 2025-09-30 | $-37.39M | (m) | (m) | $23.29M | (m) | (m) |
| 2025-06-30 | $-41.37M | (m) | (m) | $24.57M | (m) | (m) |
| 2025-03-31 | $-50.03M | (m) | (m) | $33.52M | (m) | (m) |
| 2024-12-31 | $-56.79M | (m) | (m) | $40.49M | (m) | (m) |
| 2024-09-30 | $-67.00M | (m) | (m) | $50.01M | (m) | (m) |
| 2024-06-30 | $-71.17M | (m) | (m) | $56.15M | (m) | (m) |
| 2024-03-31 | $-71.89M | (m) | (m) | $57.54M | (m) | (m) |
| 2023-12-31 | $-69.64M | (m) | (m) | $54.87M | (m) | (m) |
| 2023-09-30 | $-63.30M | (m) | (m) | $48.70M | (m) | (m) |
| 2023-06-30 | $-56.89M | (m) | (m) | $41.70M | (m) | (m) |
| 2023-03-31 | $-50.62M | (m) | (m) | $34.86M | (m) | (m) |
| 2022-12-31 | $-42.26M | (m) | (m) | $28.51M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-21.57M | (m) | (m) | $16.16M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |